Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-09-20
2005-09-20
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S135100, C424S141100, C424S144100, C424S153100, C424S155100, C424S173100, C424S174100, C424S178100, C424S181100, C424S183100, C530S387100, C530S387300, C530S388100, C530S388220, C530S388730, C530S388300, C530S388850, C530S391100, C530S391700
Reexamination Certificate
active
06946129
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
REFERENCES:
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5597569 (1997-01-01), Siegall et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5872215 (1999-02-01), Osbourne et al.
patent: 5874082 (1999-02-01), de Boer
patent: 6056959 (2000-05-01), de Boer et al.
patent: WO 96/18413 (1996-06-01), None
Schlom (Molecular Foundations of Oncology, S. Broader, Ed., 1991, pp. 95-134).
Greenwood and Clark (Effector functions of human IgG, In:Protein engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark, Ed., 1993, pp. 85-87).
Francisco et al, Journal of Biological Chemistry, 1997, vol. 272, pp. 24165-24169.
Paulie et al, Journal of Immunology, 1989, vol. 142, pp. 590-595.
Riechmann et al, Nature, 1988, vol. 332, pp. 323-327.
Greenwood et al, In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, pp. 85-100, M. Clark, Ed. 1993.
Hirano et al, Blood, 1999, vol. 9, pp. 2999-3007.
Matthews, B. “Genetic and Structural Analysis of the Protein Stability Problem”, In: Perspectives in Biochemistry, Ch 2, pp. 6-9, 1989.
Mathews and Van Holde, Biochemistry (textbook), 2nd edition, pp. 165-171, 1995.
Kim et al, “Restoring allosterism with compenatory mutations in hemoglobin”, PNAS, vol. 91, pp. 11547-11551, Nov. 1994.
Frisch et al, “A Soluble Immunoglobulin Variable Domain without a Disulfide Bridge . . . ”, Biol. Chem. Hoppe-Seyler, vol. 375, pp. 353-356, May 1994.
Bjorck et al, “Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40”, Immunology, vol. 83, pp. 430-437, Nov. 1994.
Kwekkeboom et al., “CD40 plays an essential role in the activation of human B cell by murine EL4B5 cells”, Immunology, vol. 79, pp. 439-444, Jul. 1993.
Uckun et al, “Temporal association of CD40 antigen expression with discreet stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins . . . ”, Blood, vol. 76, pp. 2449-2456.(abstract only), Dec. 1990.
Accession No. 69899, Feb. 1997.
Accession No. S67941, May 1997.
Accession No. C29380, Dec. 1988.
Accession No. W78434, Dec. 1998.
Accession No. Y06716, Mar. 1999.
Pound et al., “Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells,” Intl. Immunology, 1999, 11:11-20.
Kwekkeboom et al., “CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells,” Immunology, 1993, 79:439-44.
Alessandrini A, and Desiderio SV. 1991. Coordination of immunoglobulin DJH transcription and D-to-JH rearrangement by promoter-enhancer approximation. Mol Cell Biol. 11(4):2096-107.
Bjorck P, and Paulie S. 1996. CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation. Immunology. 87(2):291-5.
Chen et al. 1987. Nucleotide and translated amino acid sequences of cDNA coding for the variable regions of the light and heavy chains of mouse hybridoma antibodies to blood group A and B substances. J Biol Chem. 262(28):13579-83.
Tillman et al. 1992. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB x NZW)F1 mice. J Exp Med. 176(3):761-79.
Armitage et al., “Distinct patterns of inhibition by CD40 mAb of the CD40 ligand-CD40 interaction”, inLeukocyte Typing VSchlossman et al. (Eds.) 1995; 1:551-552.
Bubenik J et al., “Monoclonal antibodies against human urinary bladder carcinomas: selectivity and ultilization for gamma scrintigraphy”, Eur J Cancer Clin Oncol. Jun. 1985;21(6):701-10.
Challa A et al., “Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells”, Allergy. Jun. 1999;54(6):576-83.
Clark EA and Ledbetter JA, “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50”, Proc Natl Acad Sci U S A. Jun. 1986;83(12):4494-8.
De Paoli P, “High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernalants”, Cytometry. Feb. 15, 1997;30(1):33-8.
Fanslow et al., “CD40 mAb M2 and M3 inhibit CD40 ligand binding and function”, InLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1: 555-556.
Francisco JA et al., “Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1”, J Biol Chem. Sep. 26, 1997;272(39):24165-9.
Funakoshi S et al., “Inhibition of human B-cell lymphoma growth by CD40 stimulation”, Blood. May 15, 1994;83(10):2787-94.
Funakoshi S et al., “Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas”, J Immunother Emphasis Tumor Immunol. Mar. 1996;19(2):93-101.
Gilliland LK et al., “Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments”, Tissue Antigens. Jan. 1996;47(1):1-20.
Grafton G et al., “Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies”, Cell Immunol. Nov. 25, 1997;182(1):45-56.
Grewal IS and Flavell RA, “CD40 and CD154 in cell-mediated immunity”, Annu Rev Immunol. 1998;16:111-35.
Herbert and Callard, “Inhibition of specific antibody production by CD40L and a panel of antibodies to CD40”, inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1:552-554.
Katira et al., “CD40 Workshop Panel report”, inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1:547-550.
Katira et al., “Identification of co-operative epitopes on CD40 supprots the existence of a second CD40 ligand”, inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1:554.
Kawabe et al., “Generation and characterization of CD40-deficient mice”, inLeukocyte Typing V, Schlossman et al. (Eds.) 1995; 1:550-551.
Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death, J Immunol. Apr. 1, 1996;156(7):2345-8.
Koho H et al., “Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence”, Cancer Immunol Immunother. 1984;17(3):165-72.
Kuhne MR et al., “Assembly and regulation of the CD40 receptor complex in human B cells”, J Exp Med. Jul. 21, 1997;186(2):337-42.
Malik N et al., “Activation of human monocytes through CD40 induces matrix metalloproteinases”, J Immunol. May 15, 1996;156(10):3952-60.
Murphy WJ et al., “Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes”, Blood. Sep. 1, 1995;86(5):1946-53.
Noelle RJ et al., “A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells”, Proc Natl Acad Sci U S A. Jul. 15, 1992;89(14):6550-4.
Paulie S et al., “The human B lymphocyte and carcinoma antigen, CDw40,
Fell, Jr. Henry Perry
Francisco Joseph A.
Siegall Clay B.
Wahl Alan F.
Canella Karen A.
Conforti Vita G.
Jones Day
Seattle Genetics Inc.
LandOfFree
Recombinant anti-CD40 antibody and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant anti-CD40 antibody and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-CD40 antibody and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3442104